Today’s Stock Alert: Zeltiq Aesthetics Inc Sets All-Time High; Strong Momentum for Holders

Today's Stock Alert: Zeltiq Aesthetics Inc Sets All Time High; Strong Momentum for Holders

The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) reached all time high today, Oct, 10 and still has $56.32 target or 36.00% above today’s $41.41 share price. This indicates more upside for the $1.63 billion company. This technical setup was reported by If the $56.32 PT is reached, the company will be worth $586.80M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 100,505 shares traded hands. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has risen 69.85% since March 7, 2016 and is uptrending. It has outperformed by 62.26% the S&P500.

Analysts await Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) to report earnings on October, 25. They expect $0.07 EPS, up 40.00% or $0.02 from last year’s $0.05 per share. ZLTQ’s profit will be $2.76 million for 147.89 P/E if the $0.07 EPS becomes a reality. After $-0.12 actual EPS reported by Zeltiq Aesthetics Inc for the previous quarter, Wall Street now forecasts -158.33% EPS growth.

Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) Ratings Coverage

Out of 7 analysts covering Zeltiq Aesthetics (NASDAQ:ZLTQ), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Zeltiq Aesthetics has been the topic of 12 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Maxim Group maintained Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) on Wednesday, October 28 with “Buy” rating. The rating was maintained by Leerink Swann with “Outperform” on Wednesday, October 28. The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has “Buy” rating given on Friday, January 22 by Griffin Securities. William Blair maintained the stock with “Outperform” rating in Wednesday, August 26 report. The company was maintained on Wednesday, September 21 by Stifel Nicolaus. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, September 1. The rating was initiated by Brean Capital with “Buy” on Wednesday, April 13. The firm has “Neutral” rating given on Tuesday, August 9 by JP Morgan.

According to Zacks Investment Research, “Zeltiq Aesthetics Inc. is a medical technology company engaged in designing, development and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. The Company offers CoolSculpting System and other products to the dermatologists, plastic surgeons, and aesthetic specialists in North America and internationally. Zeltiq Aesthetics Inc. is based in Pleasanton, California.”

Insitutional Activity: The institutional sentiment increased to 1.36 in Q2 2016. Its up 0.24, from 1.12 in 2016Q1. The ratio increased, as 28 funds sold all Zeltiq Aesthetics Inc shares owned while 42 reduced positions. 25 funds bought stakes while 70 increased positions. They now own 43.91 million shares or 2.50% more from 42.84 million shares in 2016Q1.
Moreover, Bank Of New York Mellon Corp has 0% invested in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 386,392 shares. Moreover, Mycio Wealth Ltd Liability Corp has 0% invested in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 52 shares. The New Jersey-based Blackrock Investment Ltd Limited Liability Company has invested 0.01% in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Highland Cap Management Lp, a Texas-based fund reported 50,518 shares. Commercial Bank Of Montreal Can has 0% invested in the company for 3,214 shares. Wells Fargo & Company Mn, a California-based fund reported 751,061 shares. Utd Svcs Automobile Association has invested 0.01% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Teachers has invested 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Legal And General Group Incorporated Pcl has invested 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Axa accumulated 0.04% or 360,000 shares. Moreover, Swiss Savings Bank has 0% invested in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 59,800 shares. Huntington Financial Bank has 2,069 shares for 0% of their US portfolio. Raymond James Assocs last reported 18,889 shares in the company. Northern Trust Corp holds 0.01% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 606,432 shares. Calamos Advisors Ltd Llc has 696,038 shares for 0.13% of their US portfolio.

Insider Transactions: Since April 13, 2016, the stock had 0 insider purchases, and 15 selling transactions for $25.32 million net activity. FISHER MARY also sold $55,890 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) shares. Foley Mark J sold $372,564 worth of stock or 10,000 shares. On Tuesday, August 9 the insider OBOYLE KEVIN C sold $662,500. SCHIFF ANDREW N also sold $18.20M worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) shares. $150,000 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) shares were sold by Garcia Sergio. Sullivan Keith J also sold $310,719 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) shares. $90,075 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) was sold by Hauser Bradley.

Another recent and important Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) news was published by which published an article titled: “Earnings Reaction History: ZELTIQ Aesthetics, Inc., 33.3% Follow-Through …” on March 06, 2016.

ZLTQ Company Profile

ZELTIQ Aesthetics, Inc., incorporated on March 22, 2005, is a medical technology company. The Firm focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Firm sell its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment